Multigene Expression Testing in Early-Stage Breast Cancer Management

Victoria Rizk, MD, explores genomic assays to refine adjuvant therapy and capture clinical real-world evidence in breast cancer care.

Genomic assays guide adjuvant therapy in HR-positive, HER2-negative breast cancer, clarifying who benefits from chemo by age, nodal status, and risk score.

During a live event, Heather L. McArthur, MD, MPH, discussed the TAILORx trial in node-negative hormone receptor–positive/HER2-negative breast cancer.

During a live event, Heather L. McArthur, MD, MPH, reviewed genomic assays for early-stage breast cancer.

Fengting Yan, MD, PhD, discusses how her clinical practice is informed by data and guidelines available on testing in breast cancer.